AVXL — Anavex Life Sciences Share Price
0.000.00%
Last trade - 00:00- $801.30m
- $680.53m
- 32
- 18
- 97
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.7 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.22 | ||
| Price to Tang. Book | 7.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.75% | ||
| Return on Equity | -37.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 222.84 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Directors
- Christopher Missling CHM (55)
- Sandra Boenisch CFO (39)
- Adebayo Laniyonu SVP
- Walter Kaufmann CSO
- Edward Hammond OTH
- Claus van der Velden LED (48)
- Jiong Ma DRC
- Peter Donhauser IND (55)
- Athanasios Skarpelos IND (54)
- Steffen Thomas IND (55)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 23rd, 2004
- Public Since
- April 13th, 2006
- No. of Shareholders
- 48
- No. of Employees
- 42
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 85,064,199
- Address
- 630 5Th Avenue, 20Th Floor, NEW YORK, 10111
- Web
- https://www.anavex.com
- Phone
- +1 8006893939
- Auditors
- Grant Thornton LLP
Upcoming Events for AVXL
Anavex Life Sciences Corp Annual Shareholders Meeting
Anavex Life Sciences Corp Annual Shareholders Meeting
Q3 2025 Anavex Life Sciences Corp Earnings Release
Similar to AVXL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Anavex Life Sciences share price?
As of Today at 19:14 UTC, shares in Anavex Life Sciences are trading at $9.42. This share price information is delayed by 15 minutes.
How has the Anavex Life Sciences share price performed this year?
Shares in Anavex Life Sciences last closed at $9.42 and the price had moved by +177.88% over the past 365 days. In terms of relative price strength the Anavex Life Sciences share price has outperformed the S&P500 Index by +156.49% over the past year.
What are the analyst and broker recommendations for Anavex Life Sciences?
The overall consensus recommendation for Anavex Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Anavex Life Sciences dividend yield?
Anavex Life Sciences does not currently pay a dividend.
Does Anavex Life Sciences pay a dividend?
Anavex Life Sciences does not currently pay a dividend.
When does Anavex Life Sciences next pay dividends?
Anavex Life Sciences does not currently pay a dividend.
How do I buy Anavex Life Sciences shares?
To buy shares in Anavex Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Anavex Life Sciences?
As of the previous close price of $9.42, shares in Anavex Life Sciences had a market capitalisation of $801.30m.
Where are Anavex Life Sciences shares listed?
Here are the trading details for Anavex Life Sciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AVXL
What kind of share is Anavex Life Sciences?
Based on an overall assessment of its quality, value and momentum Anavex Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Anavex Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in Anavex Life Sciences is $35.97. That is 281.85% above the last closing price of $9.42.
Analysts covering Anavex Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.64 for the next financial year.
Find out moreWhat is the trend in the Anavex Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anavex Life Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +89.48%.
As of the last closing price of $9.42, shares in Anavex Life Sciences were trading +20.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Anavex Life Sciences PE Ratio?
The Anavex Life Sciences PE ratio based on its reported earnings over the past 12 months is 19.7. The shares last closed at $9.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Anavex Life Sciences?
Anavex Life Sciences' management team is headed by:
- Christopher Missling - CHM
- Sandra Boenisch - CFO
- Adebayo Laniyonu - SVP
- Walter Kaufmann - CSO
- Edward Hammond - OTH
- Claus van der Velden - LED
- Jiong Ma - DRC
- Peter Donhauser - IND
- Athanasios Skarpelos - IND
- Steffen Thomas - IND